Effectiveness of new, once-daily 5-aminosalicylic acid in the treatment of ulcerative colitis;Az új, napi egy alkalommal adagolható 5-aminoszalicilsav- készítmények hatékonysága colitis ulcerosában

Orvosi Hetilap

Volumn 150, Issue 9, 2009, Pages 397-404

  Lakatos, Péter László ^a,c   Lakatos, László ^b  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b Veszprém Megyei Csolnoky Ferenc Egyetemi Oktató Kórház   (Hungary)

^c NONE   (Hungary)

Author keywords

5 aminosalicylate; Compliance; Mesalazine; Multi Matrix System; Once daily; Therapy; Ulcerative colitis

Indexed keywords

BALSALAZIDE; MESALAZINE; OLSALAZINE; SALAZOSULFAPYRIDINE; NONSTEROID ANTIINFLAMMATORY AGENT;

CANCER RISK; CLINICAL PRACTICE; COLON CANCER; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; PATIENT COMPLIANCE; REMISSION; REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ULCERATIVE COLITIS; DRUG ADMINISTRATION; HOSPITALIZATION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; DRUG ADMINISTRATION SCHEDULE; HUMANS; MEDICATION ADHERENCE; MESALAMINE; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX;

EID: 64049095065     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2009.28555     Document Type: Review

References (41)

1. Lakatos, P. L., Fischer, S., Lakatos, L. és mtsai: Current concept on the pathogenesis of IBD: crosstalk between genetic and micro-bial factors. Pathogenic bacteria, altered bacterial sensing or changes in mucosal integrity take "toll"? World J. Gastroenterol., 2006, 12, 1829-1840.
2. Lakatos, P. L.: Recent trends in the epidemiology of infl amma-tory bowel diseases: up or down? World J. Gastroenterol., 2006, 12, 6102-6108.
3. Travis, S. P. L., Stange, E. F., Lémann, M. és mtsai: European evidence-based consensus on the management of ulcerative colitis, current management. J. Crohn Colitis, 2008, 2, 24-62.
4. Safdi, M., DeMicco, M., Sninsky, C. és mtsai: A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am. J. Gas-troenterol., 1997, 92, 1867-1871
5. Sutherland, L., MacDonald, J. K.: Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst. Rev., 2006, 2, CD000543.
6. Ransford, R. A., Langman, M. J.: Sulphasalazine and mesalazine, serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut, 2002, 51, 536-539.
7. Desreumaux, P., Ghosh, S.: Review article, mode of action and delivery of 5-aminosalicylic acid - new evidence. Aliment. Pharmacol. Ther., 2006, 24 (Suppl. 1), 2-9.
8. McCormack, P. L., Robinson, D. M., Perry, C. M.: Delayed-release multi matrix system (MMXTM) mesalazine in ulcerative colitis. Drugs, 2007, 67, 2635-2642.
9. Kane, S. V., Cohen, R. D., Aikens, J. E. és mtsa: Prevalence of nonadherence with maintenance mesalamine in quiescent ulcera-tive colitis. Am. J. Gastroenterol., 2001, 96, 2929-2933.
10. Cerveny, P., Bortlík, M., Kubena, A. és mtsai: Nonadherence in infl ammatory bowel disease, results of factor analysis. Infl amm. Bowel Dis., 2007, 13, 1244-1249.
11. Su, C., Lewis, J. D., Goldberg, B. és mtsai: A Meta-Analysis of the Placebo Rates of Remission and Response in Clinical Trials of Active Ulcerative Colitis. Gastroenterology, 2007, 132, 516- 526.
12. Prakash, A., Markham, A.: Oral delayed-release mesalazine, a review of its use in ulcerative colitis and Crohn's disease. Drugs, 1999, 57, 383-408.
13. Bantel, H., Berg, C., Vieth, M. és mtsai: Mesalazine inhibits activation of transcription factor NF-κB in infl amed mucosa of patients with ulcerative colitis. Am. J. Gastroenterol., 2000, 95, 3452- 3457.
14. Rousseaux, C., Lefebvre, B., Dubuquoy, L. és mtsai: Intestinal anti-infl ammatory effect of 5-aminosalicylic acid is dependent on per-oxisome proliferator-activated receptor-gamma. J. Exp. Med., 2005, 201, 1205-1215.
15. Osawa, E., Nakajima, A., Wada, K. és mtsai: Peroxysome prolif-erator-activated receptor gamma ligands suppress colon carcino-genesis induced by azoxymethane in mice. Gastroenterology, 2003, 124, 361-367.
16. Brunner, M., Assandri, R., Kletter, K. és mtsai: Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation. Aliment. Pharmacol. Ther., 2003, 17, 395- 402.
17. Shire Pharmaceuticals, Inc, Lialda TM, prescribing information. Wayne, PA, Shire Pharmaceuticals, 2007.
18. Sandborn, W. J., Hanauer, S. B.: Systematic review, the pharma-cokinetic profi les of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment. Pharmacol. Ther., 2003, 17, 29-42.
19. D'Haens, G., Hommes, D., Engels, L. és mtsai: Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis, a phase II, dose-ranging study. Aliment. Pharmacol. Ther., 2006, 24, 1087-1097.
20. Pierce, D., Martin, P., Kern, M. és mtsa: MMXTM mesalazine, a pharmacokinetic evaluation of dose proportionality and the effect of food. Gut 2007, 56 (Suppl. III), A158.
21. Dilger, K., Baumgaertner, E., Thomann, P.: Once-daily oral me-salazine (1.5 g/day or 3.0 g/day) does not accumulate in plasma during repeated dosing-results from a clinical trial. Gut, 2007, 56 (Suppl. III), A150.
22. Prantera, C., Viscido, A., Biancone, L. és mtsai: A new oral delivery system for 5-ASA: preliminary clinical fi ndings for MMx. In-fl amm. Bowel Dis., 2005, 11, 421-427.
23. Lichtenstein, G. R., Kamm, M. A., Boddu, P. és mtsai: Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin. Gastroenterol. Hepatol., 2007, 5, 95-102.
24. Kamm, M. A., Sandborn, W. J., Gassull, M. és mtsai: Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology, 2007, 132, 66-75.
25. Sandborn, W. J., Kamm, M. A., Lichtenstein, G. R. és mtsai: MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis, a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment. Pharmacol. Ther., 2007, 26, 205-215.
26. Schreiber, S., Karlstadt, R., Barrett, K. és mtsa: MMX mesalazine therapy for active, mild-to-moderate ulcerative colitis, time to initial symptom resolution. Gut, 2007, 56 (Suppl. III), A160.
27. Lichtenstein, G. R., Kamm, M. A., Sandborn, W. J. és mtsai: MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis, effi cacy and tolerability in specifi c patient subpopulations. Aliment. Pharmacol. Ther., 2008, 27, 1094- 1102.
28. Kruis, W., Gorelov, A., Kiudelis, G. és mtsai: Once daily dosing of 3 g mesalamine (Salofalk granules) is therapeutic equivalent to a three-times daily dosing of 1 g mesalamine for the treatment of active ulcerative colitis. Gastroenterology, 2007, 132 (Suppl. S), 898.
29. Kruis, W., Greinwald, R., Mueller, R.: Factors infl uencing therapeutic effi cacy of mesalamine (Salofalk Granules) in active ulcera-tive colitis, a combined analysis from 3 pivotal controlled studies. Gut, 2007, 56 (Suppl. S), A156.
30. Kamm, M. A., Lichtenstein, G. R., Sandborn, W. J. és mtsai: Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut, 2008, 57, 893- 902.
31. Kamm, M. A., Hanauer, S. B., Lichtenstein, G. R. és mtsai: MMX mesalamine as the sole medication for the induction and maintenance of remission of mild-to-moderate ulcerative colitis, outcome in patients treated over 14-16 months. Gastroenterology, 2007, 132 (Suppl. S), T1297.
32. The mesalamine Study Group: An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis, a randomized placebo-controlled trial. Ann. Intern. Med., 1996, 124, 204-211.
33. Lichtenstein, G. R., Diebold, R., Karlstadt, R. G. és mtsai: Patients with quiescent mild-to-moderate ulcerative colitis receiving a multiple-daily dose 5-aminosalicylic acid formulation can maintain remission with once- or twice-daily MMX mesalamine. Gas-troenterology, 2007, 132 (Suppl. S), T1295.
34. Lichtenstein, G. R., Diebold, R., Karlstadt, R. G. és mtsai: The effect of endoscopy score at the start of 5-aminosalicylic acid therapy on long-term remission rates in patients with mild-to moderate ulcerative colitis. Gastroenterology, 2007, 132 (Suppl. S), T1284.
35. Kamm, M. A., Hanauer, S. B., Diebold, R. és mtsai: Relationship between time taken to induce remission of acute mild-to-moderate active ulcerative colitis with MMX mesalazine and subsequent long-term remission rates, results from three international combined acute and maintenace studies. Gut, 2007, 56 (Suppl. III), A154.
36. Prantera, C., Kohn, A., Campieri, M. és mtsai: Once daily MMX 5-aminosalicylic acid versus twice-daily Asacol for the maintenance of remission of ulcerative colitis. Gastroenterology, 2008, 134 (Suppl. S), T1136.
37. Dignass, A., Vermeire, S., Adamek, H. és mtsai: Improved remission rates from once- versus twice-daily mesalazine (Pentasa) granules for the maintenance of remission in ulcerative colitis, results from a multinational randomised controlled trial. Gut, 2007, 56, OP-G-378.
38. Kruis, W., Laimas, J., Pokrotnieks, J. és mtsai: Once daily 3 g me-salamine is the optimal dose for maintaining clinical remission in ulcerative colitis. A double-blind, double-dummy, randomized, controlled, dose-ranging study. Gastroenterology, 2008, 134 (Suppl. S), T1124.
39. Loftus, E. V.: Epidemiology and risk factors for colorectal dyspla-sia and cancer in ulcerative colitis. Gastroent. Clin. North Am., 2006, 35, 517-531.
40. Lakatos, L., Mester, G., Erdelyi, Z. és mtsai: Risk factors for ulcera-tive colitis-associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis, results of a population-based study. Infl amm. Bowel Dis., 2006, 12, 205-211.
41. Velayos, F. S., Terdiman, J. P., Walsh, J. M.: Effect of 5-aminosali-cylate use on colorectal cancer and dysplasia risk, a systematic review and metaanalysis of observational studies. Am. J. Gastro-enterol., 2005, 100, 1345-1353.